Abstract Introduction Glucagon-like peptide-1 (GLP-1) has been the focus of considerable
research activity in the treatment of type 2 diabetes mellitus (T2DM) because the incretin …

Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2
diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists …

Introduction: Recently, glucagon-like peptide-1 receptor (GLP-1R) agonists have become
available for the treatment of type 2 diabetes. These agents exploit the physiological effects …

Novel therapeutic options for type 2 diabetes mellitus based on the action of the incretin
hormone glucagon-like peptide (GLP)-1 were introduced in 2005. As injectable GLP-1 …

Failure of secretion of the incretin hormone glucagon-like peptide-1 (GLP-1) plays a
prominent role in type 2 diabetes, and restoration of GLP-1 action is an important therapeutic …

Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists are a valuable addition to
the type 2 diabetes armamentarium. They increase insulin secretion and reduce glucagon …

The incretin system has become an important target in the treatment of type 2 diabetes in
recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose …

Introduction: GLP-1 receptor agonists have been shown to be effective in the treatment of
type 2 diabetes mellitus (T2DM). Although the first GLP-1 receptor agonist, exenatide, was …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of
antidiabetic drugs developed over the past 15 years. GLP-1, a gastrointestinal peptide …

ABSTRACT Introduction: Glucagon-like peptide-1 (GLP-1) is produced by the gut, stimulates
insulin secretion from the pancreatic β-cells, and inhibits glucagon secretion from the α-cells …